Volume 79, Issue 1, Pages 112-119 (January 2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism  Katherine Wesseling-Perry, Renata C. Pereira, Shobha Sahney, Barbara Gales, He-Jing Wang, Robert Elashoff, Harald Jüppner, Isidro B. Salusky  Kidney International  Volume 79, Issue 1, Pages 112-119 (January 2011) DOI: 10.1038/ki.2010.352 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Serum calcium (S-Ca) levels throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). Asterisk indicates P<0.01 from baseline and from sevelamer-treated patients. 1αD2, doxercalciferol; CaCO3, calcium carbonate. Kidney International 2011 79, 112-119DOI: (10.1038/ki.2010.352) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Serum phosphate (S-Phos) levels throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). 1αD2, doxercalciferol; CaCO3, calcium carbonate. Kidney International 2011 79, 112-119DOI: (10.1038/ki.2010.352) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Plasma PTH levels throughout the course of treatment. (a) Plasma PTH levels throughout the course of the study by treatment group and (b) plasma PTH levels expressed as percent change from baseline among the four treatment groups. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). Asterisk indicates P<0.01 from baseline. 1αD2, doxercalciferol; 1st PTH-IMA, first-generation parathyroid hormone immunometric assay; CaCO3, calcium carbonate. Kidney International 2011 79, 112-119DOI: (10.1038/ki.2010.352) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 Plasma FGF-23 levels throughout the course of treatment. (a) Plasma intact fibroblast growth factor-23 (FGF-23) levels throughout the course of the study by treatment group and (b) plasma C-terminal FGF-23 levels throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). Asterisk indicates P<0.01 from baseline. 1αD2, doxercalciferol; CaCO3, calcium carbonate. Kidney International 2011 79, 112-119DOI: (10.1038/ki.2010.352) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 Vitamin D sterol doses (expressed in calcitriol equivalents) throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares) and (4) calcitriol+sevelamer (open squares). 1αD2, doxercalciferol; CaCO3, calcium carbonate. Kidney International 2011 79, 112-119DOI: (10.1038/ki.2010.352) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 6 Study protocol. CaCO3, calcium carbonate; PTH, parathyroid hormone. Kidney International 2011 79, 112-119DOI: (10.1038/ki.2010.352) Copyright © 2011 International Society of Nephrology Terms and Conditions